Maze Therapeutics (MAZE) announced the appointment of Herve Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. He most recently served as CEO of Incyte Corporation (INCY) from 2014 to 2025 and as Chairman of Incyte from 2015 to 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Two new option listings on September 17th
- Maze Therapeutics price target raised to $34 from $19 at Guggenheim
- Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
- Maze Therapeutics Advances Clinical Programs Amid Financial Stability
- Maze Therapeutics price target raised to $37 from $30 at BTIG